Eteplirsen (Exondys 51)

Eteplirsen (Exondys 51) is covered only for treating Duchenne muscular dystrophy in patients with a confirmed DMD gene mutation amenable to exon 51 skipping; off‑label uses are excluded. Approval is for 12 months and requires documentation of diagnosis and genetic testing, with reauthorization contingent on documented benefit (e.g., increased dystrophin expression or improved 6‑minute walk distance) and meeting applicable safety/coverage criteria.

"For the treatment of Duchenne muscular dystrophy in an individual who has a confirmed mutation of the Duchenne muscular dystrophy gene that is amenable to exon 51 skipping"

Sign up to see full coverage criteria, indications, and limitations.